• According to the International Diabetic Federation, an estimated 643 million individuals will be diabetic by 2030.

• With the increase in diabetics, the data analysis firm GlobalData predicts rapid growth in the global diabetic device markets, particularly for continuous glucose monitors (CGMs).

• Furthermore, introducing over-the-counter CGMs (OTC CGMs) will be transformative and ensure broader accessibility for individuals with diabetes and those seeking to monitor glucose levels.

• Dexcom, the first OTC CGM approved by the FDA in March 2024, is designed for individuals aged 18 and older who do not use insulin.

• The CGM uses a wearable sensor linked to a smartphone application, providing readings every several minutes.

• These CGM devices will empower and educate individuals to manage their health.

Click here to read more.